Thoma Bravo's ~C$650M Kneat Take-Private Clears a Key Hurdle: ISS and Glass Lewis Both Recommend 'FOR' Ahead of July 30 Vote

GlobeNewswire (Kneat)·medium signal

Both major proxy advisers recommended Kneat shareholders approve Thoma Bravo's all-cash take-private at C$6.50/share (~C$650M, a 40% premium; deal announced June 8), per a July 13 GlobeNewswire release, with the shareholder vote set for July 30. Kneat digitizes validation/compliance workflows for pharma, biotech, and medical-device makers — exactly the kind of durable, regulated vertical SaaS PE is consolidating. The signal for builders: defensible compliance-workflow SaaS is a PE buy target even as horizontal tools get squeezed by AI.